{"text": ["Lilly", "gets", "U.S.", "nod", "for", "arthritis", "drug,", "sets", "price", "well", "below", "rivals"], "created_at": "2018-06-01 17:58:48"}
{"text": ["FDA", "Approves", "OLUMIANT\u00ae", "(baricitinib)", "2-mg", "Tablets", "for", "the", "Treatment", "of", "Adults", "with", "Moderately-to-Severely", "Active", "Rheumatoid", "Arthritis"], "created_at": "2018-06-01 16:04:00"}
{"text": ["FDA", "approves", "lower", "dose", "of", "Lilly-Incyte", "arthritis", "drug"], "created_at": "2018-06-01 15:24:21"}
{"text": ["A", "Closer", "Look", "at", "Novartis\u2019s", "Innovative", "Medicine", "Business"], "created_at": "2018-06-01 11:32:58"}
{"text": ["Lilly", "to", "Showcase", "New", "Data", "at", "Digestive", "Disease", "Week", "2018", "for", "Mirikizumab", "in", "Moderate-to-Severe", "Ulcerative", "Colitis"], "created_at": "2018-06-01 10:45:00"}
{"text": ["Can", "Nektar", "Therapeutics", "Disrupt", "This", "$20", "Billion", "Market?"], "created_at": "2018-06-01 03:07:02"}
{"text": ["Can", "Nektar", "Therapeutics", "Disrupt", "This", "$20", "Billion", "Market?"], "created_at": "2018-06-01 03:07:02"}
